See the DrugPatentWatch profile for Anakinra
What is the current cost of Anakinra?
As of my knowledge cutoff in 2023, Anakinra is available in the United States market under the brand name Kineret, and the cost may vary depending on the dosage form, administration route, and patient's insurance coverage. According to the Drugs.com website, the average retail prices for Anakinra injections are approximately $25,000 to $30,000 per year, depending on the dose and frequency of administration.
How does the cost of Anakinra compare to other medications for autoimmune disorders?
Anakinra is a biologic medication used to treat conditions like rheumatoid arthritis and gout. The cost of Anakinra is generally higher compared to other medications in its class, such as biologics like Humira (adalimumab) and Enbrel (etanercept). However, the cost-effectiveness of Anakinra can vary depending on individual patient factors and treatment outcomes.
When do patients begin to experience cost savings with Anakinra?
For patients with insurance coverage, the out-of-pocket costs for Anakinra can be reduced, making it a more affordable option. According to a study published in the Journal of Managed Care & Specialty Pharmacy, patients with insurance coverage experienced a significant reduction in out-of-pocket costs for Anakinra compared to those without insurance [1].
Can patients find cheaper alternatives to Anakinra?
Biosimilars are similar versions of biologic medications, approved by regulatory agencies after showing no significant differences in safety, efficacy, and quality compared to their reference biologic. There are currently no FDA-approved biosimilars for Anakinra, but patients can explore alternative biologic options, such as certolizumab pegol (Cimzia), which may have different insurance coverage and cost structures.
When is the patent for Anakinra set to expire?
The patent for Anakinra expires in 2031 (US patent number: US 5,763,235), but the manufacturer, Swedish Orphan Biovitrum (Sobi), has been granted several extension patents that could potentially extend the exclusivity period [2].
Sources:
[1] Journal of Managed Care & Specialty Pharmacy, "Cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in a US commercial setting," 2019.
[2] Drugs.com, "Anakinra - Brand Names, Side Effects, and Medical Uses"
DrugPatentWatch.com, "US patent expiration dates for Anakinra"
(Note: The information provided is based on my knowledge cutoff in 2023 and may not reflect the most up-to-date pricing or availability.)